Phathom Pharmaceuticals Inc (NASDAQ: PHAT)’s stock price has increased by 8.00 compared to its previous closing price of 7.50. However, the company has seen a 1.38% increase in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-11 that FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today it has submitted a Citizen Petition (CP) with the U.S. Food and Drug Administration (FDA). The petition formally requests correction of the Orange Book listings for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
Company’s 36-month beta value is 0.55.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PHAT is 34.87M, and currently, short sellers hold a 40.53% ratio of that floaft. The average trading volume of PHAT on December 27, 2024 was 1.29M shares.
PHAT’s Market Performance
PHAT stock saw a decrease of 1.38% in the past week, with a monthly decline of -10.89% and a quarterly a decrease of -54.55%. The volatility ratio for the week is 7.72%, and the volatility levels for the last 30 days are 7.26% for Phathom Pharmaceuticals Inc (PHAT). The simple moving average for the past 20 days is -3.17% for PHAT’s stock, with a -33.19% simple moving average for the past 200 days.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Stifel repeating the rating for PHAT by listing it as a “Buy.” The predicted price for PHAT in the upcoming period, according to Stifel is $24 based on the research report published on May 03, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $26, previously predicting the price at $23. The rating they have provided for PHAT stocks is “Buy” according to the report published on January 05th, 2024.
H.C. Wainwright gave a rating of “Buy” to PHAT, setting the target price at $28 in the report published on August 09th of the previous year.
PHAT Trading at -31.25% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.90% of loss for the given period.
Volatility was left at 7.26%, however, over the last 30 days, the volatility rate increased by 7.72%, as shares sank -9.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.28% lower at present.
During the last 5 trading sessions, PHAT rose by +1.38%, which changed the moving average for the period of 200-days by -0.86% in comparison to the 20-day moving average, which settled at $8.37. In addition, Phathom Pharmaceuticals Inc saw -11.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Nabulsi Azmi, who sale 1,118 shares at the price of $8.00 back on Dec 19 ’24. After this action, Nabulsi Azmi now owns 239,303 shares of Phathom Pharmaceuticals Inc, valued at $8,944 using the latest closing price.
Henderson Molly, the CFO and CBO of Phathom Pharmaceuticals Inc, sale 1,291 shares at $8.00 during a trade that took place back on Dec 19 ’24, which means that Henderson Molly is holding 98,156 shares at $10,328 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -10.96 for the present operating margin
- 0.85 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -12.92. The total capital return value is set at -0.89.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -15.44 points at debt to capital in total, while cash flow to debt ratio is standing at -1.41. The debt to equity ratio resting at -0.94. The interest coverage ratio of the stock is -4.33.
Currently, EBITDA for the company is -159.05 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 15.06. The receivables turnover for the company is 1.25for trailing twelve months and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.73.
Conclusion
In a nutshell, Phathom Pharmaceuticals Inc (PHAT) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
